OptimizeRx revenue jumps, leading to profit
ROCHESTER — OptimizeRx Corp. (Nasdaq: OPRX), the provider of digital health messaging for the pharmaceutical industry, reported net income of $244,928 or 2 cents a share in the third quarter …
Esperion sees positive results from final study on cholesterol-buster
ANN ARBOR — Esperion Therapeutics Inc. (Nasdaq: ESPR), the Ann Arbor-based pharmaceutical developer, announced positive results from the final Phase 3 test of its lead drug candidate, bempedoic acid. The …
OptimizeRx in new partnership for savings offers in EHR messages
ROCHESTER — OptimizeRx Corp. (NASDAQ: OPRX), the Rochester-based provider of digital health messaging for the pharmaceutical industry, has partnered with Medicom Health, a Minneapolis-based software company that creates health and …
Esperion names biotech veteran Jay P. Shepard to board
ANN ARBOR — Esperion Therapeutics Inc. (Nasdaq:ESPR), the Ann Arbor-based pharmaceutical startup developing a new class of cholesterol-lowering drugs, announced the appointment of Jay P. Shepard as a Class III …
Esperion announces another successful trial of choelsterol drug
ANN ARBOR — Esperion Therapeutics Inc. (NASDAQ:ESPR), the Ann Arbor-based cholesterol drug developer, has announced positive top-line results from the third of five pivotal Phase 3 studies (Study 3 or …
NanoBio changes name to BlueWillow Biologics, gets $10M financing
ANN ARBOR — NanoBio Corp., a clinical-stage biopharmaceutical company, announced that it has changed its corporate name to BlueWillow Biologics in conjunction with the closing of a $10 million Series …
New study, financial report from Esperion
ANN ARBOR — Esperion Therapeutics Inc. (NASDAQ:ESPR), the Ann Arbor-based pharmaceutical developer, announced positive results from the latest test of its lead drug candidate, bempedoic acid. The Phase 3 study …
Diplomat Pharmacy adds benefit management business
FLINT — Diplomat Pharmacy Inc. (NYSE: DPLO), the Flint-based specialty pharmacy services provider, has unveiled CastiaRx, a specialty benefit management business. CastiaRx unites the full-service pharmacy benefit manager capabilities of …
Esperion gets positive results in another study of cholesterol-buster
ANN ARBOR — Esperion Therapeutics Inc. (Nasdaq: ESPR), the Ann Arbor company developing new treatments for high cholesterol, announced positive rsults from a Phase 2 clinical study of its drug …
Esperion Starts Phase 3 Study of Cholesterol-Fighter
ANN ARBOR — Esperion Therapeutics Inc. (Nasdaq:ESPR), Monday announced the start of a Phase 3 study to assess the safety and efficacy of a combination pill containing its cholesterol-fighter, bempedoic …